Objective To investigate the relationship between the metabolic changes of the Cu-Zn-superoxide dismutase (CuZnSOD) and pathogenesis of the gastric carcinoma and gastric ulcer. Methods CuZnSOD activity was measured in the 52 gastric carcinoma tissues and 10 gastric ulcer tissues. The distribution and expression level of CuZnSOD in the tissues were detected by immunohistochemical staining and density analysis, respectively. Results CuZnSOD activities in the gastric carcinoma and ulcer tissues were 17.73?1.74～62.85?8.47NU/mg protein and 71.73?6.01 NU/mg protein, respectively. CuZnSOD activities in the gastric far-end tissues of the gastric carcinoma and ulcer were 25.10?3.58 ～ 101.50?11.06 NU/mg protein and 139.67?8.80 NU/mg protein, respectively. The density scales of CuZnSOD expression in the gastric carcinoma cells and tissues were 83.83?7.28 ～ 145.25?8.84 and 124.67?6.30 ～ 146.13?8.51, respectively. There was not CuZnSOD expression in the gastric ulcer tissue, while the density scales of CuZnSOD expression in the normal gastric tissue was 144.60?7.32. Conclusion The metabolic change of CuZnSOD in the gastric carcinoma tissue was related with the histological classification and differentiation of gastric carcinoma. The ability of anti-oxidation obviously declined in the both local carcinoma tissues and extensive gastric tissues. However, the ability of anti-oxidation declined only in the center of gastric ulcer.

Objective:To study the effect of Helicobacter pylori (HP) infection on the standardized dose of postoperative thyrotropin suppression of differentiated thyroid carcinoma.Methods:A total of 82 patients diagnosed with differentiated thyroid carcinoma and receiving total thyroidectomy in Beijing Rehabilitation Hospital affiliated to Capital Medical University from Jan. 2019 to Jun. 2020 were enrolled in this study prospectively.19 patients with higher standardized dose of the thyrotropin suppression (>2.5 μg·kg -1·d -1) were selected as the experimental group, and 63 patients with the lower standardized dose of the thyrotropin suppression (≤2.5 μg·kg -1·d -1) were selected as the control group. The presence of HP infection was measured by C13 method, and the HP infection rate was compared between the two groups. The patients with HP infection in the experimental group received standard quadruple therapy to eradicate Helicobacter pylori. The standardized dose before and after treatment were observed and compared. Results:The HP infection rate in the experimental group (73.7%, 14/19) were significantly higher ( P<0.05) than those in the control group (31.7%, 20/63). In the experimental group, 14 patients with HP infection in the experimental group received standard quadruple therapy to eradicate HP. HP was successfully eradicated in 11 patients after the treatment (one patient quit the treatment before completion, the actual eradication rate was 84.6%) ; Eight weeks after the treatment, the dose adjustment of thyrotropin suppression reached steady-state in 13 patients completed the therapy. The average standardized dose was (2.15±0.25) μg·kg -1·d -1, significantly lower than that before treatment [ (2.89±0.21) μg·kg -1·d -1] ( P<0.05) . Conclusions:HP infection may be an important factor affecting the standardized dose of thyrotropin suppression in postoperative patients with thyroid cancer. For those patients with HP infection, eradication treatment of HP can significantly reduce the standardized dose and treatment-related complications.